APPLICATION DEADLINE: November 1, 2019 3:00PM ET
*Applications will be reviewed on a rolling-basis.
Two postdoctoral research opportunities are available in the Division of Cellular and Gene Therapies (DCGT), within the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA) located in Silver Spring, Maryland.
Our research is focused on understanding the advanced manufacturing of CRISPR/Cas9-edited cellular therapeutics. Under the guidance of a mentor, the participants will be trained on CRISPR/Cas9 genome editing in human hematopoietic stem cells and other cell types and will use advanced manufacturing tools to better understand the ex vivo expansion and manufacturing of CRISPR-based cellular therapeutics.
Qualifications
The qualified candidate should be currently pursuing or have received a doctoral degree in one of the relevant fields. Degree must have been received within five years of the appointment start date.
Preferred skills:
- Experience with hematopoietic stem cells and CRISPR/Cas9 genome editing technology
- Strong background in molecular and cellular biology, NGS analysis, Flow cytometry, Xenotransplantation model and immunological assays
- Industrial experience in cell/gene therapy product manufacturing
For a full description of this opportunity and to submit your application, visit https://www.zintellect.com/Opportunity/Details/FDA-CBER-2019-0035.
If you have any questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2019-0035) in your email.
No comments:
Post a Comment